Engineered immune cell targeting CD19 and CD22 and application of engineered immune cell

A targeted, cellular technology, applied in the field of immunotherapy, can solve the problems of high recurrence rate and low safety
CN110157738APending Publication Date: 2019-08-23GRACELL BIOTECH SHANGHAI CO LTD
11 Cites 8 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
GRACELL BIOTECH SHANGHAI CO LTD
Publication Date
2019-08-23

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to an engineered immune cell targeting CD19 and CD22 and application of the engineered immune cell, and particularly provides a nucleic acid construct having a structure of P1-X-P2-Y (formula I), the definition of each element is as described in the specification. The engineered immune cell can recognize both CD19 and CD22 antigens, and the expression levels of two CARs targeting the CD19 and CD22 are similar in the engineered immune cell, thereby reducing immune escape risks caused by the down-regulation or loss of antigen presentation during recognition of a single-target CAR-T cell in the therapy process, and greatly reducing the difficulty of industrial application of the engineered immune cell.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to the field of immunotherapy, and more specifically relates to engineered immune cells targeting CD19 and CD22 and applications thereof. Background technique

[0002] Cellular immunotherapy is an emerging tumor treatment mode with significant curative effect, and it is a new treatment method for autoimmune anti-cancer. It is a method of using biotechnology and biological agents to culture and expand immune cells collected from patients in vitro, and then reinfuse them back into the patient's body to stimulate and enhance the body's autoimmune function, so as to achieve the purpose of treating tumors.

[0003] Chimeric antigen receptors (CARs) consist of an extracellular antigen recognition region, usually scFv (single-chain variable fragment), a transmembrane region, and an intracellular co-stimulatory signal region. The design of CARs has gone through the following process: the first-generation CAR has only one intracel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More